Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity.
Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity.
复制标题
DOI:
10.1002/jmv.27287
复制
发表时间:
2022-01
影响因子:
12.7
通讯作者:
Hartmann G
中科院分区:
文献类型:
--
作者:
Dolscheid-Pommerich R;Bartok E;Renn M;Kümmerer BM;Schulte B;Schmithausen RM;Stoffel-Wagner B;Streeck H;Saschenbrecker S;Steinhagen K;Hartmann G
In the current COVID‐19 pandemic, a better understanding of the relationship between merely binding and functionally neutralizing antibodies is necessary to characterize protective antiviral immunity following infection or vaccination. This study analyzes the level of correlation between the novel quantitative EUROIMMUN Anti‐SARS‐CoV‐2 QuantiVac ELISA (IgG) and a microneutralization assay. A panel of 123 plasma samples from a COVID‐19 outbreak study population, preselected by semiquantitative anti‐SARS‐CoV‐2 IgG testing, was used to assess the relationship between the novel quantitative ELISA (IgG) and a microneutralization assay. Binding IgG targeting the S1 antigen was detected in 106 (86.2%) samples using the QuantiVac ELISA, while 89 (72.4%) samples showed neutralizing antibody activity. Spearman's correlation analysis demonstrated a strong positive relationship between anti‐S1 IgG levels and neutralizing antibody titers (r s = 0.819, p < 0.0001). High and low anti‐S1 IgG levels were associated with a positive predictive value of 72.0% for high‐titer neutralizing antibodies and a negative predictive value of 90.8% for low‐titer neutralizing antibodies, respectively. These results substantiate the implementation of the QuantiVac ELISA to assess protective immunity following infection or vaccination. A new quantitative anti‐S1 assay (EUROIMMUN Anti‐SARS‐CoV‐2 QuantiVac ELISA IgG) was compared to a microneutralization assay. The QuantiVac ELISA showed a high level of qualitative overall agreement and a strong quantitative correlation with the results of neutralization testing. The QuantiVac ELISA has the potential to predict protective immunity against SARS‐CoV‐2 folllowing infection or vaccination.
登录
查看更多内容
DOI:
10.1093/infdis/jiaa784
发表时间:
2021-03-29
期刊:
The Journal of infectious diseases
影响因子:
--
作者:
Klingler J;Weiss S;Itri V;Liu X;Oguntuyo KY;Stevens C;Ikegame S;Hung CT;Enyindah-Asonye G;Amanat F;Baine I;Arinsburg S;Bandres JC;Kojic EM;Stoever J;Jurczyszak D;Bermudez-Gonzalez M;Nádas A;Liu S;Lee B;Zolla-Pazner S;Hioe CE
通讯作者:
Hioe CE
DOI:
10.1111/tme.12746
发表时间:
2021-06
期刊:
Transfusion medicine (Oxford, England)
影响因子:
--
作者:
Harvala H;Robb ML;Watkins N;Ijaz S;Dicks S;Patel M;Supasa P;Wanwisa D;Liu C;Mongkolsapaya J;Bown A;Bailey D;Vipond R;Grayson N;Temperton N;Gupta S;Ploeg RJ;Bolton J;Fyfe A;Gopal R;Simmonds P;Screaton G;Thompson C;Brooks T;Zambon M;Miflin G;Roberts DJ
通讯作者:
Roberts DJ
影响因子:
6.4
作者:
Jahrsdoerfer, Bernd;Kroschel, Joris;Schrezenmeier, Hubert
通讯作者:
Schrezenmeier, Hubert
影响因子:
64.8
作者:
Zost SJ;Gilchuk P;Case JB;Binshtein E;Chen RE;Nkolola JP;Schäfer A;Reidy JX;Trivette A;Nargi RS;Sutton RE;Suryadevara N;Martinez DR;Williamson LE;Chen EC;Jones T;Day S;Myers L;Hassan AO;Kafai NM;Winkler ES;Fox JM;Shrihari S;Mueller BK;Meiler J;Chandrashekar A;Mercado NB;Steinhardt JJ;Ren K;Loo YM;Kallewaard NL;McCune BT;Keeler SP;Holtzman MJ;Barouch DH;Gralinski LE;Baric RS;Thackray LB;Diamond MS;Carnahan RH;Crowe JE Jr
通讯作者:
Crowe JE Jr
影响因子:
8.8
作者:
Gasser R;Cloutier M;Prévost J;Fink C;Ducas É;Ding S;Dussault N;Landry P;Tremblay T;Laforce-Lavoie A;Lewin A;Beaudoin-Bussières G;Laumaea A;Medjahed H;Larochelle C;Richard J;Dekaban GA;Dikeakos JD;Bazin R;Finzi A
通讯作者:
Finzi A